Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46,986,408
-
Total 13F shares
-
43,904,765
-
Share change
-
+3,965,252
-
Total reported value
-
$877,180,169
-
Put/Call ratio
-
27%
-
Price per share
-
$19.95
-
Number of holders
-
159
-
Value change
-
+$94,297,658
-
Number of buys
-
80
-
Number of sells
-
67
Institutional Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q3 2025
As of 30 Sep 2025,
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) was held by
159 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
43,904,765 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, TORONTO DOMINION BANK, BlackRock, Inc., MORGAN STANLEY, Jefferies Financial Group Inc., SILVERARC CAPITAL MANAGEMENT, LLC, MILLENNIUM MANAGEMENT LLC, ACORN CAPITAL ADVISORS, LLC, and SG Americas Securities, LLC.
This page lists
159
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.